Revenue: As of FY2025, the actual value is USD 3.437 B.EPS: As of FY2025, the actual value is USD -0.15.EBIT: As of FY2025, the actual value is USD 114.4 M.<h4>BSI BioSpin Segment</h4>Revenue for the BSI BioSpin segment decreased by -3.0% to $878.8 million in 2025 from $905.7 million in 2024. Gross profit was $389.1 million with a gross profit margin of 44.3% in 2025, down from $453.9 million with a 50.1% margin in 2024. Operating income was $104.3 million (11.9% operating margin) in 2025, a decrease from $157.8 million (17.4% operating margin) in 2024. The revenue decline was primarily due to fewer GHz-class NMR system sales in 2025 (two) compared to 2024 (four), and weaker demand in the biopharma market and NMR instruments, partially offset by stronger demand in lab automation products. A goodwill impairment charge was recorded for the Automation (AUT) reporting unit in 2025.<h4>BSI CALID Segment</h4>Revenue for the BSI CALID segment increased by 10.7% to $1,210.2 million in 2025 from $1,093.5 million in 2024. Gross profit was $625.6 million with a gross profit margin of 51.7% in 2025, compared to $593.9 million with a 54.3% margin in 2024. Operating income was $153.3 million (12.7% operating margin) in 2025, down from $180.0 million (16.5% operating margin) in 2024. The revenue increase was driven by increased volumes from the Optics and Microbiology &amp; Infection Diagnostics divisions, with increased activity in Security Detection products, the MALDI Biotyper business, and the ELITechGroup molecular diagnostics business, which was acquired in Q2 2024.<h4>BSI NANO Segment</h4>Revenue for the BSI NANO segment decreased by -1.3% to $1,084.3 million in 2025 from $1,098.3 million in 2024. Gross profit was $516.3 million with a gross profit margin of 47.6% in 2025, compared to $540.4 million with a 49.2% margin in 2024. Operating income was - $71.8 million with an operating margin of -6.6% in 2025, a decrease from $2.3 million with a 0.2% margin in 2024. The revenue decline was driven by weaker demand in the academic and government research and industrial markets for analytical instruments and the Nano Surfaces and Metrology division, partially offset by NanoString, which was acquired in Q2 2024. A goodwill impairment charge was recorded for the Bruker Spatial Biology (BSB) reporting unit in 2025.<h4>BEST Segment</h4>Revenue for the BEST segment decreased by -4.3% to $270.9 million in 2025 from $283.0 million in 2024. Gross profit was $46.7 million with a gross profit margin of 17.2% in 2025, down from $61.3 million with a 21.7% margin in 2024. Operating income was $19.4 million with an operating margin of 7.2% in 2025, compared to $34.9 million with a 12.3% margin in 2024. The revenue decrease was mainly due to softness in the clinical MRI market and a strong prior-year comparison for the Research Instruments business. The increase in backlog in 2025 was primarily driven by higher BEST order bookings.<h4>Outlook / Guidance</h4>Bruker Corporation announced a cost savings initiative in August 2025, aiming to reduce annualized costs by approximately $100 million to $120 million by the end of 2026, impacting all parts of the business. The Company expects capital expenditures in 2026 to be consistent with 2025 levels, following significant investments in 2024 and prior years. Interest expense is projected to decrease in 2026, primarily due to lower debt levels after repayments made during 2025.

Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-K: FY2025 Revenue: USD 3.437 B